Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
eplerenone alvogen filmuhúðuð tafla 50 mg
alvogen ehf. - eplerenonum inn - filmuhúðuð tafla - 50 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
eplerenone alvogen filmuhúðuð tafla 25 mg
alvogen ehf. - eplerenonum inn - filmuhúðuð tafla - 25 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
eplerenon bluefish filmuhúðuð tafla 25 mg
bluefish pharmaceuticals ab - eplerenonum inn - filmuhúðuð tafla - 25 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
eplerenon krka filmuhúðuð tafla 50 mg
krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 50 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
eplerenon krka filmuhúðuð tafla 25 mg
krka, d.d., novo mesto - eplerenonum inn - filmuhúðuð tafla - 25 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
eplerenon bluefish filmuhúðuð tafla 50 mg
bluefish pharmaceuticals ab - eplerenonum inn - filmuhúðuð tafla - 50 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
inspra filmuhúðuð tafla 50 mg
upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 50 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
inspra filmuhúðuð tafla 25 mg
upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 25 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
kerendia
bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - lyf sem hafa áhrif á renín-angíótensín kerfið - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
qaialdo
nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 5.